Deceased.
1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
Consensus Report
You have free access to this content
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report
Article first published online: 29 OCT 2011
DOI: 10.1002/ibd.21870
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Additional Information
How to Cite
Feagan, B. G., Lémann, M., Befrits, R., Connell, W., D'Haens, G., Ghosh, S., Michetti, P., Ochsenkühn, T., Panaccione, R., Schreiber, S., Silverberg, M., Sorrentino, D., van der Woude, C. J., Vermeire, S. and Rutgeerts, P. (2012), Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report. Inflamm Bowel Dis, 18: 152–160. doi: 10.1002/ibd.21870
- †
Deceased.
Publication History
- Issue published online: 11 DEC 2011
- Article first published online: 29 OCT 2011
- Manuscript Accepted: 1 AUG 2011
- Manuscript Received: 25 JUL 2011
REFERENCES
- 1, , , et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244–250.
- 2, , . Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453–455.
- 3, , , et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 674–688.
- 4, , , et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990; 98: 811–818.
- 5, , , et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997; 112: 1475–1481.
- 6, , , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383–1395.
- 7, , , et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54; 237–241.
- 8, , , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European trial. Gastroenterology. 1999; 116: 1029–1034.
- 9, , , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease [ACCENT I]. Gastrointest Endosc. 2006; 63: 433–442.
- 10, , , et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic crohn's disease—first results of the Extend trial [abstract]. 2009 Digestive Diseases Week (DDW). Gastroenterology. 2009; 136( 5, suppl 1): A–116.
- 11, , , et al. Identification of subgroups of adalimumab-treated patients with Crohn's disease who experience high rates of deep remission [abstract]. 2010 European Crohn's and Colitis Organization (ECCO) Congress. Available at: https://www.ecco-ibd.eu/index.php/publications/congress-abstract-search?q=extend
- 12Remicade (infliximab) European Medicines Agency Summary of Product Characteristics, February 2011. Leiden, The Netherlands: Centocor BV. http://www.medicines.org.uk/EMC/medicine/3236/SPC/Remicade+100mg+powder+for+concentrate+for+solution+for+ infusion/#INDICATIONS
- 13Humira (adalimumab) European Medicines Agency Summary of Product Characteristics, March 2011. Berkshire, UK: Abbott Laboratories. http://www.medicines.org.uk/EMC/medicine/21201/SPC/Humira%20Pen%20and%20Syringe/#INDICATIONS
- 14Cimzia (certolizumab pegol) U.S. Food & Drug Administration Product Information, July 2010 [October 2010 approved label not online yet]. Smyrna, GA: UCB, Inc. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory
- 15, , , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. [“Step-Up Top-Down” (SUTD)] Lancet. 2008; 371: 660–667.
- 16, , , et al. Mucosal healing in adalimumab-treated patients is affected by duration of Crohn's disease: results from EXTEND [abstract]. 2011 Canadian Digestive Diseases Week (CDDW). Availabe at: http://www.cag-acg.org/uploads/cddw2011_ abstract_book_web.pdf
- 17, , , et al.; PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010; 105: 1574–1582.
- 18Linstone HA, Turoff M (eds). The Delphi Method: Techniques and Applications. Reading, MA: Addison-Wesley, 1975. p 291–321.
- 19. The Decision Delphi. Technol Forecast Soc Change. 1979; 15: 159–169.
- 20, , , et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004; 99: 91–96.
- 21, , . Prognosis in Crohn's disease—based on results from a regional patient group from the county of Copenhagen. Gut. 1985; 26: 146–150.
- 22, , , et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort [IBSEN study]. Gastroenterology. 2007; 133: 412–422.
- 23, , , et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463–468.
- 24, , , et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1295–1301.
- 25. Anti-tumor necrosis factor therapy in Crohn's disease: more information and more questions about the long term. Clin Gastroenterol Hepatol. 2010; 8: 556–558.
- 26, , , et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010; 8: 591–599.e1; quiz e78–79.
- 27, , , et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323–333.
- 28, , , et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232–1239.
- 29, , , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52–65.
- 30, , , et al. for the PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228–238.
- 31, , , et al. for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239–250.
- 32, , , et al; Precise 3 Study Investigators. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010; 8: 600–609.
- 33, . Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 524–534.
- 34, . Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol. 2010 November 3, online first. Available at: http://fg.bmj.com/content/early/2010/11/01/fg.2010.001362
- 35, , . The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response. Am J Gastroenterol. 2011; 106: 199–212.